article thumbnail

FTC order could ease biopharma competition

European Pharmaceutical Review

The biopharma company will be required to seek prior approval before acquiring related products. to address the potential competitive harm Amgen’s $27.8 We believe the government can protect competition while enhancing the value of biotech M&A activity,” John Delacourt, Deputy General Counsel for BIO declared.

article thumbnail

Biopharma sees strong Q2 2023 market cap growth

European Pharmaceutical Review

For 20 of the leading biopharmaceutical companies, the second quarter (Q2) of 2023 has brought an aggregate market capitalisation growth of 2.3 Q2 2023 biopharma market capitalisation results Eli Lilly “Eli Lilly witnessed the largest market capitalisation growth of 36.1 trillion in the Q1 of 2023 to $3.56 trillion in Q2 2023.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Sanofi drops out of competitive breast cancer drug race after another trial failure

MedCity News

Sanofi breast cancer drug amcenestrant has failed in a Phase 3 clinical trial, leading the pharmaceutical giant to discontinue all clinical development of the small molecule. The move means Sanofi is out of the competitive chase to develop a so-called “oral SERD” therapy for patients with a certain type of breast cancer.

article thumbnail

Harnessing the Power of Generational Diversity as a Competitive Advantage

PM360

As professionals with more than a half-century between us working in biopharma and diagnostics marketing and communications from the corporate (Ayaz Malik) and agency (Sandra Stahl) sides, we believe nurturing multigenerational teams is an especially powerful yet underutilized strategy for our industry.

article thumbnail

How Will Walgreens’ Expansion into Specialty Pharmacy Affect the Industry?

MedCity News

They also think Walgreens’ move could lead to greater competition, consolidation and innovation within the broader pharmacy industry. Experts think that this move could yield several strategic benefits, given the higher profit margins associated with specialty medications compared to traditional drugs.

article thumbnail

Traditional approaches to growth in biopharma are no longer sustainable

pharmaphorum

Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. Such inorganic growth is no longer viable, argues Pervaise Khan, Accenture’s UK Life Sciences Lead.

article thumbnail

J&J-Partnered Contineum Corrals $110M From IPO for Clinical Trials in Fibrosis & MS

MedCity News

Contineum Therapeutics plans to spend most of its IPO cash on clinical testing of a lead drug candidate in development for idiopathic pulmonary fibrosis and multiple sclerosis. This small molecule blocks a competitive target pursued by several other companies, including Bristol Myers Squibb and AbbVie.